Lamivudine Mylan (Lamivudine)

Lamivudine is a nucleoside analogue that is converted inside cells to its active triphosphate form. This active metabolite competes with natural nucleotides for incorporation by the viral reverse transcriptase enzyme. Once incorporated, it lacks a 3′‑hydroxyl group, causing premature termination of the viral DNA chain and blocking replication of HIV and hepatitis B virus.

The specific dose of lamivudine is determined by the prescribing clinician based on the patient’s age, weight, renal function, and the condition being treated. Dosage regimens differ for HIV versus hepatitis B and may be adjusted when used in combination with other antiretroviral agents.

Safety of lamivudine in pregnancy and lactation should be evaluated by the treating physician. The drug is classified as Category C in many regions, indicating that potential benefits may justify use despite limited data. Breastfeeding decisions should consider the infant’s exposure and the mother’s clinical status.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lamivudine Mylan. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and once‑daily dosing in many regimens. Compared with older NRTIs such as zidovudine, lamivudine has fewer mitochondrial toxicities. When combined with drugs from other classes (e.g., integrase inhibitors), it contributes to potent, durable viral suppression.

Store Lamivudine Mylan at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Lamivudine Mylan is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and not miss doses.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, yellowing of the skin or eyes, or a severe rash.

Lamivudine Mylan should be avoided in individuals with known hypersensitivity to lamivudine or any of the tablet’s excipients. Caution is also advised for patients with severe renal impairment, active liver disease, or those taking medications that have major interactions, such as didanosine or stavudine.